PROTAC 2’ cut toxic expanded huntingtin aggregates in Huntington’s disease cells and mouse models, while leaving healthy huntingtin forms largely unchanged.
The compound works by binding the distinct shape of expanded HTT clumps and recruiting the cell’s protein-disposal machinery to degrade them.
In cell experiments, lower insoluble HTT levels were paired with reduced cellular stress and improved survival, supporting the idea that the targeted clumps are especially harmful.
In mice carrying about 120 CAG repeats, treatment reduced HTT clumps, improved brain markers and motor-like symptoms, and extended lifespan versus untreated HD mice.
The findings point to a potentially safer protein-clearance strategy than broad HTT suppression, though brain delivery and larger studies remain hurdles before human use.
Could this 'protein-pruning' technology be the key to defeating not just Huntington's, but also Alzheimer's and Parkinson's?
After a similar drug's recent FDA approval, could this new molecule finally treat Huntington's disease at its source?
How does this large molecule bypass the brain's powerful defenses, a challenge that has stumped drug developers for decades?
PROTAC 2′ for Huntington’s Disease: A Preclinical Breakthrough Targeting Mutant Huntingtin with Precision and Promise
Overview
Huntington's disease is a devastating neurodegenerative disorder, and finding effective treatments remains a major challenge. PROTAC 2′, developed by the Huang lab, is a new compound in preclinical testing that offers hope for patients. Unlike traditional drugs, PROTAC 2′ is designed to target the root cause of Huntington's disease by recruiting both the toxic mutant huntingtin protein clumps and the cell's natural degradation machinery to the same place. This unique approach helps break down harmful protein aggregates, potentially slowing disease progression and sparing healthy proteins, making PROTAC 2′ a promising step forward in Huntington's disease research.